Search

Selected EMA news

February 2025New medicines recommended for approval
Dyrupeg (pegfilgrastim) – biosimilar
Treatment to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy

Eltrombopag Accord (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C
New information on…

Read more

Belgium shares EU health priorities for Council Presidency

On December 8, Belgium held a conference to unveil its program for the upcoming Council of the EU Presidency (website), to start on January 1, 2024.

Read more

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes

Date: November 15-17, 2024
Location: Paris, France

Chairpersons: Carmem Bonfim, Tim Brümmendorf, Antonio Risitano, Sharon Savage
Scientific Committee: Beatrice Drexler, Carlo Dufour, Morag Griffin, Régis Peffault de Latour

With the support of the Severe Aplastic…

Read more

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more